Jasper Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JSPRW | GUD.TO | IMCR | CLYM | KRYS | KY4.F | |
|---|---|---|---|---|---|---|
| Market cap | — | 1.11B | 1.51B | 535.88M | 9.21B | 7.59B |
| P/E (TTM) | — | 75.3 | — | — | 42.2 | 16.9 |
| Forward P/E | — | 43.5 | -37.7 | -9.3 | 34.0 | 17.7 |
| Price/book | 0.0 | 1.4 | 3.6 | 2.2 | 6.4 | 1.5 |
| Dividend yield | — | — | — | — | — | 2.89% |
| 1-year change | — | +86.16% | −7.49% | +378.46% | +55.44% | +1.49% |
| Today | −84.62% | +0.36% | −2.66% | −4.31% | +1.90% | +6.62% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All JSPRW news ›Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
The Manila Times REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper” or the "Company”), a clinical stage biotechnology company focused on the design and development of innovative…
More from 1 other outlet
Jasper Therapeutics puts up to 604M shares to a vote
VivoPower Signs Definitive Heads of Agreement with Open Innovation AI to Develop Secure Sovereign AI Data Centers Across the Nordics, Mainland Europe, the GCC and selective countries in Asia China SXT Pharmaceuticals Inc Announces…
Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104 Phase 2 Study
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104…
Jasper Therapeutics registers up to 284M resale shares
Stockholders approved an amendment allowing a 1-for-15 to 1-for-35 reverse split; the board may effect it on or before December 31, 2026. After the earlier of approval or the 12-month anniversary, holders can require cash at fair value if…
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Profusa Receives ISO 13485:2016 Certificate from GMED The kidney-disease study is expanding beyond IgA nephropathy, with first-patient dosing in an additional cohort anticipated in early 2027. Jasper expects initial interim IgA nephropathy…
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at William Blair
Posted by Kim Johansen on Oct 14th, 2026 Equities researchers at William Blair started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) in a report issued on Wednesday. The brokerage set an “outperform” rating on…
Jasper Therapeutics completes 18-patient IgAN enrollment
Nexera Technologies: Fort Technology’s Subsidiary Logia USA Signs Exclusive Distribution Agreement to Expand Fuel Maintenance Solutions for Data Centers Across the U.S. INVE Technologies Announces the Commencement of a $20 Million Modified…
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Tendered warrants will be cancelled; purchasing all outstanding warrants would require approximately $4.0 million from cash on hand. Jasper Therapeutics (JSPR) commenced an offer to purchase all outstanding warrants issued in its September…
Jasper Therapeutics offers $0.324 cash per warrant
The Warrants were issued as part of Jasper Therapeutics' September 18, 2025 underwritten public offering. As filed with the Securities and Exchange Commission on October 7, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net8
- seekingalpha.com2
- tradingview.com2
- globenewswire.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.